)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Curasight
Curasight (CURAS) investor relations material
Curasight Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary29 May, 2026
Executive summary
Advanced uPAR-targeted theranostic platform with progress in both UTREAT® therapy and UTRACE® diagnostics during Q1 2026, including encouraging preliminary Phase 1 data in high-grade gliomas.
Strengthened Board with two international healthcare leaders, enhancing expertise in radioligand therapy and commercialization.
Increased visibility through participation in major healthcare conferences and strategic investor engagement.
Completed partial conversion of convertible loan, reducing debt and broadening long-term shareholder base.
Financial highlights
Gross loss for Q1 2026 was KDKK -13,078, compared to KDKK -4,699 in Q1 2025.
Operating loss amounted to KDKK -15,278 (Q1 2025: KDKK -6,209); loss before tax was KDKK -16,704 (Q1 2025: KDKK -6,579).
Loss for the period was KDKK -15,329, up from KDKK -5,204 year-over-year.
Cash at March 31, 2026, was KDKK 22,088, compared to KDKK 1,514 a year earlier.
Equity ratio improved to 19.0% from 14.2% year-over-year.
Earnings per share was DKK -0.32 (Q1 2025: DKK -0.25).
Outlook and guidance
Focus remains on advancing clinical development of UTREAT® and UTRACE®, with key milestones expected in 2026, including additional clinical data and patient enrollment.
Anticipates increased strategic and commercial interest in radiopharmaceuticals, leveraging recent industry momentum.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Curasight
- Losses increased but cash and equity improved, with major clinical and financing milestones achieved.CURAS
Q4 20252 Mar 2026 - Advanced clinical pipeline and strong cash position despite higher losses year-over-year.CURASQ3 202527 Nov 2025
- Rights issue targets DKK 100 million to fund key cancer studies and extend cash runway to 2026.CURASInvestor Update15 Nov 2025
- Strengthened financials and clinical momentum with key trials advancing in prostate and brain cancer.CURASQ2 202528 Aug 2025
- Curasight achieved major clinical and financing milestones, strengthening its position in radiopharma.CURASQ3 202413 Jun 2025
- Losses widened but new funding and clinical progress extended the cash runway into H2 2025.CURASQ2 202413 Jun 2025
- Curasight opens a DKK 100 million rights issue, with 47% secured by commitments.CURASInvestor Update6 Jun 2025
- Q1 2025 saw reduced losses and major funding secured to advance uTRACE and uTREAT platforms.CURASQ1 20256 Jun 2025
- Curasight accelerated clinical development and strengthened its financial base despite higher losses.CURASQ4 20245 Jun 2025
Next Curasight earnings date
Q2 202627 Aug, 2026
Curasight
Next Curasight earnings date
Q2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage